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Abstract
Introduction: To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients 
treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT).
Methods: Univariate analyses and multivariate linear regression analyses assessed risk for radiographic progression 
(change in modified total Sharp score, ΔmTSS > 0.5) from baseline to week 24 for C-reactive protein (CRP) and other 
baseline variables, and for 24-week time-averaged CRP (univariate analysis only). Subanalyses determined mean ΔmTSS 
for CRP subgroups. Analyses were post hoc, with observed data.
Results: One hundred and forty-four adalimumab-treated patients and 152 placebo-treated patients were assessed. 
Mean CRP was 64% lower by week 2 with adalimumab and essentially unchanged with placebo. Univariate analyses 
indicated that elevated CRP at baseline and time-averaged CRP were strongly associated with radiographic 
progression for placebo-treated patients but not for adalimumab-treated patients. Multivariate analysis confirmed that 
elevated baseline CRP was the only strong independent risk factor for radiographic progression (for CRP ≥1.0 mg/dl: 
odds ratio = 3.28, 95% confidence interval = 1.66 to 6.51, P < 0.001). Adalimumab treatment reduced risk of progression 
approximately fivefold. The difference between mean ΔmTSS for adalimumab versus placebo was greatest for patients 
with baseline CRP ≥2.0 mg/dl (-0.5 vs. 2.6).
Conclusions: Systemic inflammation in PsA, as indicated by elevated baseline CRP, was the only strong independent 
predictor of radiographic progression. This association was observed predominantly for placebo-treated patients. 
Adalimumab treatment substantially reduced the overall risk of radiographic progression, and provided greatest 
radiographic benefit for patients with the greatest CRP concentrations at baseline.
Trial Registration: Trial registration: NCT00195689.
Introduction
Psoriatic arthritis (PsA) is an inflammatory arthritis
found in up to approximately 30% of patients with psoria-
sis and in 0.3 to 1% of the general population [1]. PsA was
previously considered a mild form of arthritis, typically
less severe than rheumatoid arthritis (RA). Evidence has
accumulated, however, to show that PsA is associated
with substantial morbidity [2-5]. Progression of clinical
and radiographic damage in PsA has been related to dis-
ease activity and severity, both at presentation and at fol-
low-up [6]. Progressive erosive disease had been reported
in more than one-half of patients with PsA and is often
associated with functional impairment [2,3,7,8]. Patients
with PsA are at increased risk of death compared with the
general population [9], and severity of PsA at presenta-
tion is a predictor of mortality [10].
Before the advent of biologic agents, therapies were
employed in PsA based on experience in RA, despite dif-
ferences in the types of joint damage typical of each dis-
ease and despite the lack of evidence to support
prevention of clinical or radiographic damage in PsA.
Randomized controlled trials of traditional disease-modi-
fying antirheumatic drugs for patients with PsA have not
included radiographic assessments, and data from an
observational study provided no evidence that disease-
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modifying antirheumatic drugs prevented radiographic
damage in PsA [11]. In contrast, randomized controlled
t r i a l s  w i t h  a n t i - T N F  a g e n t s  i n  p a t i e n t s  w i t h  P s A  h a v e
demonstrated not only clinical efficacy, but also signifi-
cant inhibition of radiographic progression [12-17].
The Adalimumab Effectiveness in PsA Trial (ADEPT) is
one of the largest randomized, double-blind, placebo-
controlled trials of a TNF antagonist for treatment of PsA
to date. ADEPT demonstrated that 24 weeks of treatment
with adalimumab improved arthritis, skin disease and
quality of life, and prevented radiographic joint destruc-
t i o n  i n  pa t i e n ts  wi t h  P s A  [ 1 3 ] .  S u b a n a l y s es  o f  AD E PT
have suggested that radiographic progression was associ-
ated with several baseline factors, including elevated val-
ues of C-reactive protein (CRP), swollen joint count
(SJC), and tender joint count (TJC) [14]. It is not known
which factors, if any, were independently associated with
radiographic progression in ADEPT.
CRP is a sensitive marker for systemic inflammation.
Elevated concentrations of CRP have been associated
with radiographic progression in RA [18,19]. PsA and RA
have distinct types of joint pathology, however, so they do
not necessarily have identical risk factors for joint dam-
age. In addition, CRP is not always elevated in patients
with clinically active arthritis. The aim of this post hoc
analysis was therefore to extend previous studies in PsA
by determining whether CRP or other factors were inde-
pendent predictors of radiographic progression in
ADEPT. We found that baseline CRP, as measured with a
high-sensitivity assay, was the dominant independent
predictor of radiographic progression, and that the rela-
tionship between CRP and radiographic progression was
different for patients treated with placebo compared with
adalimumab.
Materials and methods
ADEPT study design
ADEPT was a phase III, randomized, double-blind, pla-
cebo-controlled trial in which patients were randomized
to receive subcutaneous placebo or adalimumab 40 mg
every other week. Randomization was centrally stratified
by methotrexate use (yes/no) and extent of psoriasis (<
3% or ≥3% body surface area (BSA)) at baseline. Radio-
graphs of the hands and feet were obtained at baseline
and week 24, and were read by two blinded readers using
a modified version of the total Sharp score (mTSS) that
included assessments of distal interphalangeal joints [13].
Clinical and laboratory assessments were performed
throughout the study, as previously described [13].
ADEPT was conducted in accordance with the princi-
ples of the Declaration of Helsinki (2000), and the proto-
col was approved by the institutional review boards of the
participating centers. All patients provided written
informed consent before any study-related procedures
were initiated [13].
Patients
The present analysis included all patients in ADEPT for
whom radiographs had been obtained at baseline and
week 24. ADEPT eligibility criteria required a minimum
of three tender joints and three swollen joints, active pso-
riatic skin lesions or a history of psoriasis, and a history of
an inadequate response or intolerance to nonsteroidal
anti-inflammatory drugs. Eligibility criteria are described
in greater detail elsewhere [13].
Clinical and laboratory assessments
Numbers of joints evaluated were 78 for TJC and 76 for
SJC. Serum CRP was assessed at a central laboratory with
a high-sensitivity assay (upper limit of normal = 0.287
mg/dl), for samples obtained at baseline and weeks 2, 4, 8,
12, 16, 20 and 24. Anti-cyclic citrullinated peptide anti-
bodies were not measured in ADEPT.
Predictor variables
Variables tested as risk factors for radiographic progres-
sion included the following baseline measures: treatment
received (adalimumab vs. placebo), patient age, PsA dis-
ease duration, psoriasis disease duration, continuous
CRP, categorical CRP (≤0.287 vs. > 0.287 mg/dl; < 1.0 vs.
≥1.0 mg/dl; < 2.0 vs. ≥2.0 mg/dl), mTSS, joint erosion (JE)
score, joint space narrowing (JSN) score, SJC, TJC, body
weight, methotrexate use (yes/no), and rheumatoid factor
(positive/negative). For the univariate analyses only, 24-
week time-averaged CRP was also tested as a predictor
variable.
Outcome measure
The outcome measure for univariate and multivariate
analyses was radiographic progression, defined as a
change in modified total Sharp score (ΔmTSS) > 0.5 from
baseline to week 24 (yes/no). The mTSS value of 0.5 was
chosen because it is an accepted threshold that has been
previously used to assess radiographic progression in
ADEPT [14] and early RA [20].
Subgroup analyses
Mean ΔmTSS from baseline to week 24 was determined
for patients grouped post hoc by baseline CRP concentra-
tion (< 1.0 vs. ≥1.0 mg/dl); by baseline CRP concentration
using the following four categories: ≤0.287 mg/dl, > 0.287
to < 1 mg/dl, ≥1.0 to < 2.0 mg/dl, and ≥2 mg/dl; and by
time-averaged CRP concentration each using the follow-
ing four categories: ≤0.287 mg/dl, > 0.287 to < 1 mg/dl,
≥1.0 to < 2.0 mg/dl, and ≥2 mg/dl. These four categories
were chosen to represent CRP concentrations that are
normal (for the high-sensitivity assay employed in
ADEPT), slightly elevated (or approximately normal, forGladman et al. Arthritis Research & Therapy 2010, 12:R113
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nonhigh-sensitivity assays), moderately elevated, and
very elevated, respectively. Mean CRP concentrations
were determined for patients grouped by whether they
had radiographic progression (ΔmTSS > 0.5) or not
(ΔmTSS ≤0.5) from baseline to week 24.
Cumulative probability plots
Cumulative probability plots were generated to depict
ΔmTSS results for all patients by treatment arm, with
separate curves for patients with baseline CRP < 1.0 mg/
dl and baseline CRP ≥1.0 mg/dl.
Statistical analyses
Summary statistics were provided for baseline variables
by treatment group. The mean and standard deviation
were summarized for continuous variables, and the num-
ber and percentage of patients for categorical variables.
Differences between treatment groups for the change
from baseline in CRP by visit were analyzed by an analy-
sis of variance model with treatment group and baseline
methotrexate use/extent of psoriasis as factors (yes/≥3%
BSA, yes/< 3% BSA, no/≥3% BSA, no/< 3% BSA). Within
each CRP subgroup (≤0.287 mg/dl, > 0.287 to < 1.0 mg/dl,
< 1.0 mg/dl, ≥1.0 mg/dl, ≥1 to < 2.0 mg/dl, and ≥2.0 mg/
dl), differences between treatment groups were compared
using an analysis of covariance model, with treatment as a
factor and ranked baseline mTSS as the covariate for
changes in mTSS at week 24. For each patient, time-aver-
aged CRP (in mg/dl) was determined as the area under
t he  cu rve  of  CRP va l ues fr o m  base l ine  t o w ee k  24 ( in
units of mg/dl-weeks), divided by 24 weeks.
Univariate analyses were performed using logistic
regression models for each treatment separately and
combined to determine potential associations between
radiographic progression and each predictor variable.
Multivariate analysis using a logistic regression model
was performed for selected baseline variables, including
all that were statistically significant (P < 0.05) in the uni-
variate analysis, except for JSN and JE scores (to prevent
duplication with mTSS). The multivariate analysis was
performed four times: once with CRP as a continuous
variable, and three times with CRP as a dichotomous
variable (once each at a threshold of 0.287, 1.0 and 2.0
mg/dl). The results for non-CRP risk factors are reported
from the analysis with CRP as a dichotomous variable at a
threshold of 0.287 mg/dl.
All statistical tests were two-sided and considered sig-
nificant at α = 0.05. P < 0.05 was considered statistically
significant. All data are observed, without imputation;
except for the mean CRP values determined according to
radiographic progression (yes/no), which used the last
observation carried forward for missing data.
Results
This post hoc analysis included the 152 placebo-treated
patients and 144 adalimumab-treated patients from
ADEPT who had evaluable radiographs at baseline and
24 weeks. There were no differences at baseline in demo-
graphic or disease-related features between these treat-
ment groups (Table 1), or between each group and the
intention-to-treat cohort from which it derived [13]. The
mean values for Δm TSS from baseline to week 24 were
1.0 for patients treated with placebo versus -0.2 for those
treated with adalimumab (P < 0.001) [13]. Radiographic
progression (defined as ΔmTSS > 0.5) from baseline to
week 24 was observed in 44 of 152 (29%) patients treated
with placebo versus 13 of 144 (9%) treated with adali-
mumab (P < 0.001) [14]. The mean CRP concentration
was essentially unchanged during 24 weeks of placebo
treatment, whereas with adalimumab the concentration
had declined by 63% at week 2 and varied minimally
thereafter (Figure 1).
Univariate analyses of factors potentially associated with 
radiographic progression
Univariate analyses of the combined placebo-treated and
adalimumab-treated groups showed that baseline CRP
(whether analyzed as a continuous or a dichotomous
variable), baseline mTSS, and baseline JE and JSN scores
were each predictive (P < 0.05) of radiographic progres-
sion (Table 2). Treatment with adalimumab was protec-
tive from radiographic progression. The 24-week time-
averaged CRP, an indicator of treatment effect, was sig-
nificantly associated with radiographic progression in
this univariate analysis.
Univariate analyses were also performed with the pla-
cebo and adalimumab groups considered separately, to
determine whether they differed in their risk factors for
radiographic progression. For placebo-treated patients,
the strongest positive associations with radiographic pro-
gression (that is, greatest odds ratio (OR)) were observed
for baseline CRP as a dichotomous variable (at CRP
thresholds > 0.287 mg/dl, ≥1.0 mg/dl and ≥2.0 mg/dl),
baseline CRP as a continuous variable, and mean CRP
over time (Table 2). Baseline mTSS, JE score, and JSN
score were also associated with progression for placebo-
treated patients, and baseline psoriasis duration was
associated with protection against progression. For adali-
mumab-treated patients, the only OR that was signifi-
cantly different from unity was for baseline CRP ≥1.0
(Table 2). Univariate analyses thus demonstrated that
inflammation, as indicated by an elevated CRP at baseline
or over time, was more strongly associated with radio-
graphic progression for patients who received placebo,
than for patients who received adalimumab.Gladman et al. Arthritis Research & Therapy 2010, 12:R113
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Relationship between C-reactive protein and radiographic 
progression
Subanalyses were performed to elucidate the relationship
between CRP and radiographic progression. At baseline,
CRP was < 1.0 mg/dl for 91 of 152 (60%) patients in the
placebo arm versus 95 of 144 (66%) in the adalimumab
arm (P = 0.282). For patients treated with placebo versus
adalimumab, the mean ΔmTSS was 0.5 versus -0.2 (P <
0.001) for those with baseline CRP < 1.0 and was 1.9 ver-
sus 0.0 (P < 0.001) for those with baseline CRP ≥1.0 mg/dl
(Figure 2a). To assess ΔmTSS across a spectrum of CRP
values, patients were analyzed in four categories of base-
line CRP. The mean ΔmTSS values were greater with pla-
cebo than with adalimumab for three of the four CRP
categories, with the greatest difference (2.6 vs. -0.5)
observed between the groups with baseline CRP ≥2.0 mg/
dl (Figure 2a). For patients with baseline CRP values ≥1.0
to < 2.0 mg/dl, the mean ΔmTSS values were similar for
placebo and adalimumab - reflecting the small numbers
of patients and the fact that, of the eight greatest ΔmTSS
values observed among adalimumab-treated patients, five
occurred in this CRP group (with the other three being in
patients with baseline CRP ≥2.0 mg/dl). A similar pattern
of results was obtained for patients grouped by four cate-
gories of mean CRP over time, with the mean ΔmTSS
being greatest for the placebo-treated groups with great-
est time-averaged CRP, and ≤0 for each adalimumab
group (Figure 2c).
These results demonstrate that an elevated CRP was
less important as a risk factor for radiographic progres-
sion with adalimumab than placebo. Poorly controlled
inflammation, however, may have influenced radio-
graphic progression during adalimumab therapy because
Table 1: ADEPT baseline demographics and disease severity characteristics
Characteristic Placebo (n = 152) Adalimumab 40 mg every other week (n = 144)
Age (years)a 49.4 ± 11.1 47.8 ± 11.9
Male (%) 55.3 56.3
White (%) 94.1 97.2
Body weight (kg)a 85.4 ± 16.4 86.1 ± 20.5
Psoriatic arthritis duration (years)a 9.3 ± 8.8 9.9 ± 8.3
Psoriasis duration (years)a 16.8 ±12.4 17.2 ± 12.1
Modified total Sharp score (0.5 (%)b 16.4 11.8
Modified total Sharp scorea 20.0 ± 36.3 22.3 ± 46.6
Joint erosion score 10.5 ± 20.2 11.4 ± 25.9
Joint space narrowing score 9.5 ± 17.3 10.9 ± 21.8
CRP (0.287 mg/dl (%)c 22.4 19.4
CRP (mg/dl)a 1.4 ± 1.7 1.4 ± 2.1
Rheumatoid factor-negative (%) 90.1 89.6
Patients taking methotrexate at baseline (%) 51.3 51.4
Tender joint count (0 to 78 joints)a 25.8 ± 17.9 23.6 ± 17.4
Swollen joint count (0 to 76 joints)a 14.4 ± 11.4 13.6 ± 11.6
HAQ Disability Index (0 to 3)a 1.0 ± 0.7 1.0 ± 0.6
HAQ, Health Assessment Questionnaire. P > 0.2 for all adalimumab vs. placebo. aMean ± standard deviation. bAbsence of radiographic 
progression, defined as modified total Sharp score ≤0.5. cNormal C-reactive protein (CRP) by high-sensitivity assay, defined as ≤0.287 mg/dl.
Figure 1 Mean C-reactive protein concentrations over time. Se-
rum concentrations of C-reactive protein (CRP) were determined from 
baseline to week 24 for patients treated with placebo or adalimumab 
in ADEPT. Data are presented as mean values at each time point. Data 
are observed; n values at baseline/week 24 were 152/146 for placebo 
and 143/138 for adalimumab. P < 0.001 for the comparison of mean 
changes from baseline for adalimumab versus placebo at all time 
points after week 0.
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the eight greatest increases in mTSS values observed dur-
ing adalimumab therapy occurred in patients with base-
line CRP ≥1.0 mg/dl. Moreover, the mean CRP
concentration for adalimumab-treated progressors (n =
13) was essentially unchanged by treatment (Figure 2c),
whereas for adalimumab-treated nonprogressors (n =
131) the mean concentration was markedly reduced by
treatment (Figure 2d).
Cumulative probability plots of ΔmTSS by C-reactive 
protein concentration at baseline
To further clarify the relationship between baseline CRP
and joint damage, radiographic outcomes were evaluated
with cumulative probability plots of ΔmTSS from base-
line to week 24. The placebo curve was above the adali-
mumab curve (indicating a worse overall radiographic
outcome with placebo) for patients with baseline CRP <
1.0 mg/dl (Figure 3a) and, to a greater degree, for patients
with baseline CRP ≥1.0 mg/dl (Figure 3b). With adali-
mumab, radiographic progression occurred almost only
among patients with baseline CRP ≥1.0 mg/dl, and was
never as great as in the most severe cases observed with
placebo. Improvement in mTSS (seen in the left-hand
side of a curve) was more prominent among adali-
mumab-treated patients, especially among those with
baseline CRP ≥1.0 mg/dl. These cumulative probability
plots demonstrate that the radiographic efficacy of adali-
mumab, as measured in ADEPT, represented reduced
worsening and greater improvement of mTSS.
Multivariate analysis of baseline factors associated with 
radiographic progression
A multivariate logistic regression analysis was performed
to determine whether CRP or other baseline factors iden-
tified in the univariate analyses were independently asso-
ciated with radiographic progression. The analysis
considered all patients as a single group, and included the
baseline variables that were statistically significant in the
univariate analyses, as well as selected demographic vari-
ables (Table 3). The results demonstrated that an elevated
baseline CRP concentration was an independent predic-
tor for radiographic progression, whether CRP was
assessed as a continuous variable (OR = 1.16, 95% confi-
dence interval (CI) = 1.01 to 1.33, P = 0.040) or a dichoto-
mous variable (for CRP > 0.287: OR = 4.31, 95% CI = 1.42
to 13.09, P = 0.010; for CRP ≥1.0: OR = 3.28 95% CI = 1.66
to 6.51, P < 0.001; and for CRP ≥2.0: OR = 2.29 95% CI =
1.12 to 4.69, P = 0.023). An elevated mTSS at baseline was
Table 2: Univariate analyses of predictors for radiographic progression
Placebo-treated patients Adalimumab-treated patients All patients
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Treatment with adalimumaba NA NA NA NA NA NA 0.24 0.13, 0.48 < 0.001
CRP (time-averaged) 1.74 1.33, 2.28 < 0.001 1.48 0.99, 2.22 0.058 1.84 1.47, 2.30 < 0.001
CRP (continuous) 1.40 1.12, 1.75 0.003 1.05 0.84, 1.31 0.684 1.18 1.03, 1.35 0.017
CRP > 0.287 mg/dla 5.50 1.59, 19.09 0.007 3.12 0.39, 25.02 0.285 4.25 1.47, 12.24 0.007
CRP (1.0 mg/dla 3.98 1.90, 8.32 < 0.001 3.51 1.08, 11.39 0.036 3.82 2.09, 6.99 < 0.001
CRP (2.0 mg/dla 4.40 2.05, 9.45 < 0.001 1.34 0.34, 5.23 0.676 3.46 1.87, 6.42 < 0.001
Age 1.00 0.97, 1.03 0.954 1.02 0.97, 1.07 0.399 1.01 0.98, 1.04 0.484
RF-positivea 1.45 0.46, 4.60 0.530 1.65 0.33, 8.27 0.542 1.41 0.57, 3.49 0.458
Swollen joint count 1.02 0.99, 1.06 0.122 1.01 0.97, 1.06 0.657 1.02 1.00, 1.04 0.100
Tender joint count 1.00 0.98, 1.02 0.741 1.01 0.98, 1.04 0.459 1.01 0.99, 1.02 0.358
mTSS 1.03 1.01, 1.04 < 0.001 1.00 0.995, 1.01 0.365 1.01 1.00, 1.02 0.001
Joint erosion 1.05 1.02, 1.08 < 0.001 1.01 0.99, 1.02 0.490 1.02 1.01, 1.03 0.001
Joint space narrowing 1.05 1.03, 1.08 < 0.001 1.01 0.99, 1.03 0.264 1.02 1.01, 1.04 0.001
Methotrexate (yes)a 1.37 0.67, 2.77 0.387 2.15 0.63, 7.33 0.222 1.47 0.82, 2.64 0.201
PsA duration 1.00 0.96, 1.04 0.816 1.03 0.97, 1.10 0.337 1.00 0.97, 1.04 0.896
Psoriasis duration 0.97 0.93, 0.998 0.039 1.03 0.99, 1.08 0.140 0.99 0.96, 1.01 0.277
Weight 1.01 0.99, 1.03 0.450 1.00 0.97, 1.03 0.848 1.00 0.99, 1.02 0.717
CI, confidence interval; CRP, C-reactive protein; mTSS, modified total Sharp score; NA, not applicable; OR, odds ratio; PsA, psoriatic arthritis; RF, 
rheumatoid factor. All variables are at baseline, except CRP (time-averaged). aDichotomous variables - those without a footnote annotation are 
continuous variables.Gladman et al. Arthritis Research & Therapy 2010, 12:R113
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the only other independent predictor of radiographic
progression, but the increase in risk was small (OR = 1.01,
95% CI = 1.00 to 1.02, P = 0.002). Treatment with adali-
mumab was a strong independent predictor of decreased
radiographic progression, with a nearly fivefold reduction
in frequency of radiographic progression (OR = 0.21, 95%
CI = 0.10 to 0.42, P < 0.001).
Discussion
The goals of treatment in patients with PsA are to control
symptoms and signs of inflammation and to prevent pro-
gression of joint damage. The present post hoc analysis
has extended previous studies of joint damage in PsA
[6,13,14] by identifying factors that independently pre-
dicted radiographic progression in a randomized, pla-
cebo-controlled study of PsA (ADEPT). Furthermore, it
determined whether these factors had similar effects for
patients treated with adalimumab versus those treated
with placebo. The principal finding, obtained from a mul-
tivariate linear regression analysis, was that an elevated
baseline CRP concentration was the dominant indepen-
dent risk factor for radiographic progression in PsA.
Treatment with adalimumab was the dominant predictor
for reduced radiographic progression.
Univariate analyses demonstrated that elevated base-
line CRP was strongly associated with radiographic pro-
gression only for placebo-treated patients. In contrast,
while almost no radiographic progression occurred
among adalimumab-treated patients with baseline CRP <
1.0 mg/dl, those with baseline CRP ≥2.0 mg/dl had the
best overall radiographic outcomes; that is, the lowest
mean ΔmTSS. These results indicate that the baseline
CRP concentration was a predictor of which patients with
PsA were at risk for subsequent joint damage, that adali-
mumab was effective for preventing most joint damage in
PsA, and that the greatest radiographic benefit from adal-
Figure 2 Mean change in modified total Sharp score for C-reactive protein subgroups. Changes in modified total Sharp score (ΔmTSS) from 
baseline to week 24 with standard error were determined for patients grouped post hoc by (a) baseline C-reactive protein (CRP) categorized as < 1 
mg/dl and ≥1 mg/dl, (b) baseline C-reactive protein (CRP) categorized as ≤0.287 mg/dl, > 0.287 to < 1 mg/dl, ≥1.0 to < 2.0 mg/dl, and ≥2 mg/dl, and 
(c) 24-week time-averaged CRP categorized as ≤0.287 mg/dl, > 0.287 to < 1 mg/dl, ≥1.0 to < 2.0 mg/dl, and ≥2 mg/dl. (d) Mean CRP values at baseline 
and week 24, with standard error, were determined for patients grouped according to whether they had radiographic progression (ΔmTSS > 0.5) be-
tween baseline and week 24. Data are observed; except for CRP values in (c), which used the last observation carried forward for missing values. *P < 
0.05, **P < 0.01, ***P ≤0.001, †P = 0.052 vs. placebo.Gladman et al. Arthritis Research & Therapy 2010, 12:R113
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imumab occurred for patients with the greatest baseline
CRP concentrations.
Cumulative probability plots demonstrated that adali-
mumab prevented nearly all radiographic progression
among patients with baseline CRP < 1.0 mg/dl and, com-
pared with placebo, most radiographic progression
among patients with baseline ≥CRP 1.0 mg/dl (Figure 3).
They also illustrated that the mTSS did not increase for a
substantial portion of placebo-treated patients, including
some with baseline CRP ≥1.0 mg/dl. This finding was not
attributable to concomitant use of methotrexate [14] and
was too frequent to have been caused only by spontane-
ous improvements in clinical arthritis activity [13].
Instead, the absence of radiographic progression in some
patients probably reflects true disease heterogeneity, plus
several quantitative factors - including the tendency for
PsA to cause radiographically detectable joint damage
less frequently than RA, the limited duration of placebo-
controlled observation in ADEPT (24 weeks), and the
ability of radiographs to detect only a portion of total
joint damage [21].
The magnitude of radiographic benefit observed here
with adalimumab is probably a low estimate compared
with what might have been observed if adalimumab and
placebo had been compared over a longer period of time.
Consistent with this expectation, adalimumab inhibited
radiographic progression in patients from ADEPT to 48
weeks [14] and to 2 years [22]. Although baseline CRP
was < 1.0 mg/dl in a smaller portion of patients treated
with placebo (60%) than adalimumab (66%; P = 0.282) in
ADEPT, the overall radiographic efficacy of adalimumab
[13] cannot be explained by this difference because mean
Figure 3 Cumulative probability plots of mean change in modified total Sharp score. Cumulative probability plots displaying the changes in 
modified total Sharp score (ΔmTSS) from baseline to week 24 were generated for (a) patients with baseline C-reactive protein (CRP) < 1.0 mg/dl and 
(b) patients with baseline CRP ≥1.0 mg/dl. For each CRP category, the placebo curve is above the adalimumab curve, indicating greater radiographic 
progression.
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Table 3: Multivariate analysis of predictors for radiographic progression
Variable OR 95% CI P value
Treatment with adalimumaba 0.21 0.10, 0.42 < 0.001
CRP (continuous) 1.16 1.01, 1.33 0.040
CRP > 0.287 mg/dla 4.31 1.42, 13.09 0.010
CRP (1.0 mg/dla 3.28 1.66, 6.51 < 0.001
CRP (2.0 mg/dla 2.29 1.12, 4.69 0.023
Modified total Sharp score 1.01 1.00, 1.02 0.002
CI, confidence interval; CRP, C-reactive protein; OR, odds ratio. Separate multivariate analyses were performed for CRP (continuous), CRP > 
0.287 mg/dl, CRP ≥1.0 mg/dl and CRP ≥2.0 mg/dl. For non-CRP variables, results are from the analysis with CRP > 0.287 mg/dl. All multivariate 
analyses also included baseline age, rheumatoid factor (yes/no), tender joint count, swollen joint count, and methotrexate use (yes/no) as 
variables; P > 0.05 for each. aDichotomous variables - those without a footnote annotation are continuous variables.Gladman et al. Arthritis Research & Therapy 2010, 12:R113
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ΔmTSS was significantly lower with adalimumab, regard-
less of whether baseline CRP was < 1.0 mg/dl or ≥1.0 mg/
dl.
This analysis also found that radiographic joint damage
at baseline was an independent predictor of radiographic
progression. The magnitude of this association was small
in the multivariate analysis, both in absolute terms and
when compared with the results for baseline CRP vari-
ables (Table 3). Baseline joint damage also predicted pro-
gression of damage in a previous observational cohort
study [6]. In that study, tender and swollen joints were
identified as independent predictors of radiographic pro-
gression [6]; in the current study, however, TJC and SJC
were predictive of progression only in the univariate anal-
ysis, not in the multivariate analysis. This disparity
between studies may be related to the finding that CRP
was a stronger predictor of joint damage than were the
physical examination-based indicators of arthritic
inflammation. The disparity may also be related to the
greater joint counts at baseline in ADEPT (mean values
of 24 tender joints and 14 swollen joints), compared with
the observational cohort study [6].
The present study focused mainly on evaluating base-
line measures as predictors of joint damage. It also exam-
ined the role of treatment effect, by assessing patients in
terms of their 24-week time-averaged CRP. For placebo-
treated patients, the association between ΔmTSS and
time-averaged CRP was similar to that observed between
ΔmTSS and baseline CRP, probably because an elevated
CRP tends to remain elevated without treatment (Figure
2d). For adalimumab-treated patients, the mean ΔmTSS
was inhibited regardless of the concentration of time-
averaged CRP. Adalimumab thus appeared to inhibit
radiographic progression not only by reducing inflamma-
tion, but also via effects that were not entirely dependent
on control of inflammation. These findings are consistent
with evidence that TNF antagonists can directly inhibit
the osteoclast pathway in patients with PsA [23,24], and
with radiographic outcomes observed in patients with RA
[21,25,26]. Further research is needed to understand vari-
ations in responses to TNF antagonists, not only for indi-
vidual patients, but also with respect to destructive versus
proliferative joint disease in PsA.
The main limitation of the analyses presented here is
that they were designed post hoc. ADEPT is a unique
resource because it is the only randomized controlled
trial of a TNF antagonist in PsA that continued placebo
therapy for 24 weeks without an escape option. The 24-
week duration limited the ΔmTSS in placebo-treated
patients to a mean value of 1.0, however, and did not
allow radiographic efficacy to be assessed in the full study
population after an initial period of therapy. The number
of adalimumab-treated patients with radiographic pro-
gression was small, which precluded subset analyses in
this group. The mTSS used for ADEPT was modified for
PsA by including the distal interphalangeal joints, but it
only measured erosions and joint space narrowing and
only in peripheral joints. Other PsA-related radiographic
findings were assessed in ADEPT, such as juxtaarticular
periostitis and pencil-in-cup. They changed by amounts
that were too small to warrant their inclusion in the pres-
ent analysis [14].
Conclusions
We have shown that an elevated CRP concentration at
baseline was an independent predictor of radiographic
progression for patients with PsA. This risk relationship
was strong only for patients treated with placebo. Treat-
ment with adalimumab rapidly reduced the mean CRP
concentration, and was an independent predictor of
reduced radiographic progression in PsA. Adalimumab
inhibited radiographic progression across the spectrum
of baseline or time-averaged CRP, doing so by preventing
nearly all progression in patients with baseline CRP < 1.0
mg/dl and greatly limiting it in others. These analyses
demonstrate that patients with the greatest elevations in
baseline CRP were at greatest risk for joint damage if
untreated, and were the ones who derived greatest radio-
graphic benefit when treated with adalimumab.
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